All six IPAC Members participating in the meeting updated their declarations of interest ahead of the 11-13 June 2019 meeting. Other participants, including observers, do not take part in the decision-making and are thus not required to complete a declaration of interest.

Four IPAC Members reported relevant interests, all of which were assessed not to constitute a conflict of interest and these individuals will take part in full in all the discussions.

All the reported relevant interests are summarized below.

**Craig Burgess**
- Is employed by JSI Research & Training Institute. Within the past 4 years his institute has received various levels of support from Gavi, BMGF and USAID for a variety of projects, these include: Dose Per Container Partnership; multiple cold chain and supply chain strengthening projects; new vaccine introduction (especially HPV and rotavirus vaccine) in multiple countries; and urban projects in multiple countries. This interest was assessed as non-personal, specific and financially significant.*
- As an employee of JSI Research & Training institute is personally involved in rotavirus vaccine introduction in Myanmar, Laos and Nepal, and in urban immunization in Indonesia, DRC and India. This interest was assessed as non-personal, specific and financially significant.*
- Is a Gavi Board Member for Civil Society Organisations and is engaged in a number of projects with CSOs. This interest was assessed as personal, specific and financially significant.*
- Is engaged with post 2020 vaccine vision work. This interest was assessed as personal, specific and financially insignificant.*
- Is engaged with the UHC Civil Society Engagement Mechanism (CSEM) of UHC2030 and is helping to plan for the high-level meeting in September on Universal Health Coverage. This interest was assessed as personal, non-specific and financially insignificant.*

**Michael Free**
- Was employed as Vice President and Senior Advisor for technology solutions for Path until 2014. Is now retired.
- Chairs the advisory STAG for the NEST 360 project at Rice University. The project is developing a number of technologies for maternal and child health. Most are for emergency care, but vaccine-related technologies could come up in the future. This interest was assessed as personal, non-specific and financially insignificant.*

---

* According to WHO’s Guidelines for Declaration of Interests (WHO expert), an interest is considered “personal” if it generates financial or non-financial gain to the expert, such as consulting income or a patent. “Specificity” states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has “financial significance” if the honoraria, consultancy fee or other received funding, including those received by expert’s organization, from any single vaccine manufacturer or other vaccine-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in excess of 1,000 USD would also constitute a “significant shareholding”.

---
- Is on the Advisory Committee for the SafePoint Trust in the UK. This trust focuses on promoting safe injection primarily in the LMCs. This interest was assessed as personal, specific and financially significant.*
- Advises the UNITUS Ventures in India. This is an impact investment fund that focuses on education, health and small business. It occasionally reviews requests for funding for health technologies, none of which have been for vaccine-related technologies, but could possibly arise in the future. This interest was assessed as personal, non-specific and financially insignificant.*
- Review proposals for the Japanese GHIT Fund which occasionally includes vaccine-related technologies. This interest was assessed as personal, specific and financially insignificant.*

Ian Gemmill
- Has participated in three advisory boards for pneumococcal vaccine for Pfizer since the 2018 IPAC Meeting for which he received payment. This interest was assessed as personal, non-specific and financially insignificant.*

Kelly Moore
- Was employed until 2018 as Director of the Tennessee Immunization Program, for the Tennessee Department of Health (TDH). As such, she was required to analyze proposed state legislation and offer expert advice to the Executive Branch on any legislation related to immunization. This interest was previously assessed as non-personal, non-specific and financially significant and has since ceased.*
- Is receiving consulting fees as a Special Government Employee as a member of the Advisory Committee on Immunization Practices (ACIP) for the United States of America’s CDC. This interest was assessed as personal, non-specific and financially insignificant.*
- Is employed as a consultant to the Puerto Rico Cancer Center on an evaluation of the implementation of an HPV vaccine school requirement in Puerto Rico. This interest was assessed as personal, non-specific and financially insignificant.*
- Provides expert testimony in regulatory processes, representing positions: voting members of the US ACIP publicly provide their positions during policy debates and their votes are binding on the federal Vaccines for Children Program and certain commercial insurance plans. This interest was assessed as non-personal, non-specific and financially insignificant.*
- In her capacity as Director of Immunization for Tennessee Department of Health (TDH), she was required to testify on Department’s behalf on immunization bills under consideration by the legislature. This interest was assessed as non-personal, non-specific and financially insignificant.*